Invention Grant
- Patent Title: Treatment of IL-17 mediated disease by blocking SEFIR-SEFIR interactions
-
Application No.: US14354608Application Date: 2012-10-29
-
Publication No.: US09611295B2Publication Date: 2017-04-04
- Inventor: Xiaoxia Li , Caini Liu , Junpeng Deng , Thomas A. Hamilton , Jarod Zepp
- Applicant: THE CLEVELAND CLINIC FOUNDATION
- Applicant Address: US OH Cleveland
- Assignee: The Cleveland Clinic Foundation
- Current Assignee: The Cleveland Clinic Foundation
- Current Assignee Address: US OH Cleveland
- Agency: Tarolli, Sundheim, Covell & Tummino LLP
- International Application: PCT/US2012/062380 WO 20121029
- International Announcement: WO2013/063557 WO 20130502
- Main IPC: C07K14/00
- IPC: C07K14/00 ; C07K7/08 ; C07K7/06 ; A61K38/08 ; A61K38/10 ; A61K38/16
Abstract:
A method of treating an IL-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the SEFIR domain of IL-17R to the SEFIR domain of Act1. In particular, it has been determined that the αC helix region of the SEFIR domain of both IL-17R and Act1 plays an important role in the association of IL-17R and Act1. To facilitate cell permeation, the decoy peptide is preferably conjugated to a protein transduction domain. Examples of IL-17 mediated diseases include various human and animal inflammatory and autoimmune diseases such as asthma.
Public/Granted literature
- US20150158912A1 TREATMENT OF IL-17 MEDIATED DISEASE BY BLOCKING SEFIR-SEFIR INTERACTIONS Public/Granted day:2015-06-11
Information query
